AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|
25.9 C
New York
Thursday, July 30, 2026

Tag: heart muscle

newssourceFORcompanyinformationcontent1releasesmarket

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

Medmovie Launches HxHeart.com, Bringing Its Trusted Cardiovascular Education Library to Any Browser — and Releases a New Video on the Hidden Risks of Coronary...

The same clinician-approved animations from the Hx Heart app are now available online at HxHeart.com — free, instantly, with no download required.BERKELEY, Calif., June...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHeart muscle

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers